Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

被引：0

作者：

Leleu, Xavier ^{[1
,2
]}

Beksac, Meral ^{[3
]}

Chou, Takaaki ^{[4
]}

Dimopoulos, Meletios ^{[5
]}

Yoon, Sung-Soo ^{[6
]}

Prince, Henry Miles ^{[7
]}

Pour, Ludek ^{[8
]}

Shelekhova, Tatiana ^{[9
]}

Chari, Ajai ^{[10
]}

Khurana, Monica ^{[11
]}

Obreja, Mihaela ^{[11
]}

Qi, Ming ^{[12
]}

Oriol, Albert ^{[13
]}

Siegel, David ^{[14
]}

机构：

[1] Chu, Poitiers, France

[2] Inserm 1402CIC, Poitiers, France

[3] Ankara Univ, Ankara, Turkey

[4] Niigata Canc Ctr Hpt, Niigata, Japan

[5] Natl & Kapodistrian Univ Athens, Sch Med, Hematol & Med Oncol, Dept Clin Therapeut,Sch Med, Athens, Greece

[6] Seoul Natl Univ, Seoul, South Korea

[7] Peter MacCallum Canc Inst, East Melbourne, Australia

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Clin Profess Pathol, Saratov, Russia

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[11] Amgen Inc, Thousand Oaks, CA USA

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[14] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MM; multiple myeloma; carfilzomib; cross-study comparison; weekly dosing; KdD;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-040

引用

页码：S288 / S288

页数：1

共 41 条

[31] MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Korde, Neha
Mastey, Donna
Mailankody, Sham
Hassoun, Hani
Lesokhin, Alexander M.
Smith, Eric L.
Lendvai, Nikoletta
Hultcrantz, Malin
Tavitian, Elizabet
Salcedo, Meghan
Sams, Allison
Diab, Victoria
Chung, David J.
Scordo, Michael
Lahoud, Oscar B.
Landau, Heather J.
Arcila, Maria E.
Giralt, Sergio
Ho, Caleb
Roshal, Mikhail
Devlin, Sean M.
Dogan, Ahmet
Landgren, Ola
BLOOD, 2018, 132
[32] MRD Response-Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Korde, Neha
Mailankody, Sham
Smith, Eric L.
Lendvai, Nikoletta
Hassoun, Hani
Lesokhin, Alexander
Hultcrantz, Malin
Chung, David J.
Shah, Gunjan L.
Koehne, Guenther
Landau, Heather
Roshal, Mikhail
Dogan, Ahmet
Giralt, Sergio A.
Mastey, Donna
Evancha, Nicole
Devlin, Sean M.
Landgren, Ola
BLOOD, 2017, 130
[33] A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Lendvai, Nikoletta
Hilden, Patrick
Devlin, Sean
Landau, Heather
Hassoun, Hani
Lesokhin, Alexander M.
Tsakos, Ioanna
Redling, Kaitlyn
Koehne, Guenther
Chung, David J.
Schaffer, Wendy L.
Giralt, Sergio A.
BLOOD, 2014, 124 (06) : 899 - 906
[34] Carfilzomib 20/45 or 20/56 mg/m2 infused over 30 min in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma
Badros, Ashraf
Papadopoulos, Kyriakos P.
Zojwalla, Naseem
Ruey, Ju
Lee, Jiuan
Siegel, David S.
LEUKEMIA & LYMPHOMA, 2013, 54 : 17 - 18
[35] Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy
Berdeja, Jesus
Rifkin, Robert
Lyons, Roger
Cartmell, Alan
Coleman, Morton
Yang, Hui
Zahlten-Kumeli, Anita
Iskander, Karim
Berenson, James
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E58 - E59
[36] Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
Tang, Yong
Yu, Ye-hua
Yao, Yi-yun
Zou, Li-fang
Dou, Hong-ju
Wang, Lei
Zhu, Qi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 22 - 30
[37] Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
Yong Tang
Ye-hua Yu
Yi-yun Yao
Li-fang Zou
Hong-ju Dou
Lei Wang
Qi Zhu
Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 22 - 30
[38] Once-Weekly 1.6mg/m2 Bortezomib BCD Regimen in Newly Diagnosed Multiple Myeloma: Better Response and Lower Incidence of Peripheral Neuropathy
Li, Fangfang
Li, Hao
Li, Yubin
Zhan, Zhumei
Song, Wangshan
Li, Fanglin
Li, Xiangxin
Wang, Lingling
Wang, Yan
Wang, Luqun
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E211 - E211
[39] Survival, efficacy and safety of weekly docetaxel (35 mg/m2) plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma
Berdjis, N.
Rodemer, G.
Ehlers, S.
Wismann, T.
Rodemer, Y.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S705 - S705
[40] Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
Yong, Kwee
Popat, Rakesh
Wilson, William
Pang, Gavin
Jenner, Richard
De Tute, Ruth M.
Ramasamy, Karthik
Streetly, Matthew
Cavenagh, Jamie
Sive, Jonathan
Chapman, Michael
Bygrave, Ceri
Phillips, Beth
Chavda, Selina J.
Virchis, Andres E.
Benjamin, Reuben
Arnott, Sarah
Willis, Fenella
Hassan, Sandra
Moore, Sally
Clifton-Hadley, Laura
Owen, Roger G.
BLOOD, 2019, 134

← 1 2 3 4 5 →